PE20070592A1 - Derivados de prolinamida como moduladores de canales de sodio - Google Patents

Derivados de prolinamida como moduladores de canales de sodio

Info

Publication number
PE20070592A1
PE20070592A1 PE2006001225A PE2006001225A PE20070592A1 PE 20070592 A1 PE20070592 A1 PE 20070592A1 PE 2006001225 A PE2006001225 A PE 2006001225A PE 2006001225 A PE2006001225 A PE 2006001225A PE 20070592 A1 PE20070592 A1 PE 20070592A1
Authority
PE
Peru
Prior art keywords
prolinamide
sodium channel
channel modulators
fluorophenyl
phenyl
Prior art date
Application number
PE2006001225A
Other languages
English (en)
Spanish (es)
Inventor
Giuseppe Alvaro
Riccardo Giovannini
Roberto Profeta
Markus Bergauer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20070592A1 publication Critical patent/PE20070592A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
PE2006001225A 2005-10-10 2006-10-06 Derivados de prolinamida como moduladores de canales de sodio PE20070592A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
PE20070592A1 true PE20070592A1 (es) 2007-06-23

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001225A PE20070592A1 (es) 2005-10-10 2006-10-06 Derivados de prolinamida como moduladores de canales de sodio

Country Status (20)

Country Link
US (2) US7655693B2 (https=)
EP (1) EP1934177B8 (https=)
JP (1) JP5139305B2 (https=)
KR (1) KR101282464B1 (https=)
AR (1) AR056575A1 (https=)
AT (1) ATE556049T1 (https=)
AU (1) AU2006301470B2 (https=)
BR (1) BRPI0616944B8 (https=)
CA (1) CA2625642C (https=)
CR (1) CR9898A (https=)
EA (1) EA015736B1 (https=)
ES (1) ES2387405T3 (https=)
IL (1) IL192627A0 (https=)
MA (1) MA29817B1 (https=)
NO (1) NO20082145L (https=)
NZ (1) NZ567051A (https=)
PE (1) PE20070592A1 (https=)
PL (1) PL1934177T3 (https=)
TW (1) TW200730494A (https=)
WO (1) WO2007042239A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) * 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
JP5855000B2 (ja) * 2009-09-14 2016-02-09 クオンベルゲンセ プハルマセウトイカルス リミテッド α−カルボキサミド誘導体の製造方法
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP3110794A1 (en) 2014-02-27 2017-01-04 Merck Patent GmbH Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 新規投薬レジメン
MX2019013758A (es) * 2017-05-19 2020-07-20 Biogen Ma Inc Formas cristalinas novedosas.
CA3076823A1 (en) 2017-10-05 2019-04-11 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
CA3077088A1 (en) 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives
KR20210002472A (ko) * 2018-04-16 2021-01-08 바이오젠 엠에이 인코포레이티드 신경병증성 통증을 치료하는 방법
MX2021012421A (es) * 2019-04-10 2022-02-10 Biogen Inc Procesos para preparar derivados de pirrolidina alfa-carboxamida.
AU2020271856A1 (en) * 2019-04-10 2021-12-02 Biogen Ma Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
US12544385B2 (en) 2020-01-30 2026-02-10 Mohammad JAVED Combination drug therapies for CNS disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
CA2368631A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク エンド カムパニー インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
EP1618099A4 (en) 2003-04-18 2008-07-16 Merck & Co Inc BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
EP1877381A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US7858786B2 (en) 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20080280969A1 (en) 2008-11-13
NO20082145L (no) 2008-05-07
BRPI0616944B1 (pt) 2020-04-14
WO2007042239A1 (en) 2007-04-19
EP1934177A1 (en) 2008-06-25
EP1934177B1 (en) 2012-05-02
IL192627A0 (en) 2011-08-01
NZ567051A (en) 2011-03-31
ATE556049T1 (de) 2012-05-15
JP2009511519A (ja) 2009-03-19
JP5139305B2 (ja) 2013-02-06
EA015736B1 (ru) 2011-10-31
CA2625642C (en) 2013-12-24
PL1934177T3 (pl) 2013-03-29
EP1934177B8 (en) 2012-09-05
ES2387405T3 (es) 2012-09-21
AU2006301470A1 (en) 2007-04-19
BRPI0616944B8 (pt) 2021-05-25
US8153681B2 (en) 2012-04-10
EA200801054A1 (ru) 2008-08-29
KR101282464B1 (ko) 2013-07-04
CR9898A (es) 2008-07-29
MA29817B1 (fr) 2008-09-01
AU2006301470B2 (en) 2012-06-14
CA2625642A1 (en) 2007-04-19
BRPI0616944A2 (pt) 2011-07-05
AR056575A1 (es) 2007-10-10
US20100105754A1 (en) 2010-04-29
TW200730494A (en) 2007-08-16
KR20080059296A (ko) 2008-06-26
US7655693B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
PE20070592A1 (es) Derivados de prolinamida como moduladores de canales de sodio
PE20090888A1 (es) Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119
CR11470A (es) Compuestos organicos
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
PE20090730A1 (es) Derivados de piridina como moduladores de los canales de sodio
ECSP099621A (es) Derivados de ciclohexano espirociclico
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
CL2011000159A1 (es) Compuestos derivados de 1,3-oxazin-2-ona, inhibidores de 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
ECSP10010273A (es) Tratamiento de plantas de plátano y papa con una nueva composición antifúngica
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
PA8855001A1 (es) Monocarbamas
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
GT200600475A (es) Derivados de pirazina
NO20085317L (no) Imidazoazepinonforbindelser
UY29486A1 (es) Compuestos utiles en terapia
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5
AR057869A1 (es) Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto
PE20090953A1 (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace
AR062475A1 (es) Combinaciones farmacologicas para el tratameinto de enfermedades de las vias aereas
PA8772401A1 (es) Macrólidos
AR106180A2 (es) COMPUESTO DE a-AMINOCARBOXIAMIDA QUE ES 5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)PROLINAMIDA

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed